Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H32N4 |
Molecular Weight | 244.42 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNCCCNCCCNCCCNCC
InChI
InChIKey=UMJJGDUYVQCBMC-UHFFFAOYSA-N
InChI=1S/C13H32N4/c1-3-14-8-5-10-16-12-7-13-17-11-6-9-15-4-2/h14-17H,3-13H2,1-2H3
Molecular Formula | C13H32N4 |
Molecular Weight | 244.42 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Diethylnorspermine is the structural analog of polyamines. Polyamines were shown to downregulate polyamine synthesis and uptake, upregulate polyamine catabolism, and result in a profound depletion of polyamines. Diethylnorspermine is adenosylmethionine decarboxylase, ornithine decarboxylase inhibitor and spermidine-spermine N1-acetyltransferase stimulant. Diethylnorspermine is under investigation as a novel anticancer drug for a variety of neoplasms. It has sustained inhibitory effects on the growth of human prostate carcinoma cells in vitro as well in vivo. This polyamine analog may provide a new tool in the chemotherapy of prostate cancers with various phenotypes. Diethylnorspermine was relatively well tolerated in patients with advanced hepatocellular carcinoma (HCC) including those with mild-to-moderate liver dysfunction but further evaluation of diethylnorspermine monotherapy for advanced HCC does not appear to be justified because of insufficient evidence of clinical benefit in the patients evaluated in this study. Also, no evidence of clinical activity was detected in metastatic breast cancer treatment (phase II clinical study).
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14676116
100 mg/m2 as a 15-min infusion on days 1-5 every 21 days
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:59:32 GMT 2023
by
admin
on
Fri Dec 15 17:59:32 GMT 2023
|
Record UNII |
HLI827Z1ST
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
182803
Created by
admin on Fri Dec 15 17:59:32 GMT 2023 , Edited by admin on Fri Dec 15 17:59:32 GMT 2023
|
||
|
NCI_THESAURUS |
C49109
Created by
admin on Fri Dec 15 17:59:32 GMT 2023 , Edited by admin on Fri Dec 15 17:59:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C1168
Created by
admin on Fri Dec 15 17:59:32 GMT 2023 , Edited by admin on Fri Dec 15 17:59:32 GMT 2023
|
PRIMARY | |||
|
4282
Created by
admin on Fri Dec 15 17:59:32 GMT 2023 , Edited by admin on Fri Dec 15 17:59:32 GMT 2023
|
PRIMARY | |||
|
DB06445
Created by
admin on Fri Dec 15 17:59:32 GMT 2023 , Edited by admin on Fri Dec 15 17:59:32 GMT 2023
|
PRIMARY | |||
|
DTXSID50923952
Created by
admin on Fri Dec 15 17:59:32 GMT 2023 , Edited by admin on Fri Dec 15 17:59:32 GMT 2023
|
PRIMARY | |||
|
HLI827Z1ST
Created by
admin on Fri Dec 15 17:59:32 GMT 2023 , Edited by admin on Fri Dec 15 17:59:32 GMT 2023
|
PRIMARY | |||
|
121749-39-1
Created by
admin on Fri Dec 15 17:59:32 GMT 2023 , Edited by admin on Fri Dec 15 17:59:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |